American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB 18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB 18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Minimal Symptom Expression With Claseprubart, an Active C1S Inhibitor, in Patients With Generalized Myasthenia Gravis 1.4 MB 18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB 18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.3 MB Congress of the European Academy of Neurology (EAN) 2026 June 27, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.6 MB Pagination Current page 1 Page 2 Page 3 Next page › Last page »
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB
Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB
Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB
Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB
CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB
Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB
18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB
CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB
18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Minimal Symptom Expression With Claseprubart, an Active C1S Inhibitor, in Patients With Generalized Myasthenia Gravis 1.4 MB
Minimal Symptom Expression With Claseprubart, an Active C1S Inhibitor, in Patients With Generalized Myasthenia Gravis 1.4 MB
18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB
Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB
18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.3 MB
Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.3 MB
Congress of the European Academy of Neurology (EAN) 2026 June 27, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.6 MB
Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.6 MB
